The $15B Nuclear Bet With Zero Revenue Looks Safer Than the One Actually Selling
Oklo remains pre-revenue with substantial cash runway while NuScale faces massive one-time charges, dilution, and a severe earnings miss despite a TVA win.
Viking Therapeutics, NuScale Power, and Lemonade show high short interest and recent price rallies, increasing short-squeeze potential amid company-specific bullish catalysts.